Innovation Pharmaceuticals Inc (IPIX)

[FlashingLeather]

Yes it is. I think the entire purpose of the back-ended interim is to transfer as much data as possible to interested counterparties so that they can begin their own internal evaluation processes (modeling, scenario analysis, DD, discussions, etc.) for either partnership or asset purchase.

Numbers matter as there is currently a very wide range of valuations based on drug efficacy, so the more certainty in the data, the better to narrow down what the asset is truly worth. Agree with Sox that 100% is best, but due to the trial's recruitment issues, they will probably back off that target a bit to ensure a Q3 release.

Sharing interim results with Big Pharma under a confidentiality agreement is a different story.